Communiqués Mineralys Therapeutics, Inc.

Actions

MLYS

US6031701013

Temps réel estimé Cboe BZX Autres places de cotation 16:45:06 04/06/2024			Varia. 5j.	Varia. 1 janv.
13,06 ^USD	-0,19%		+7,73%	+52,33%

16/05	Transcript : Mineralys Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 05:01 PM
09/05	Transcript : Mineralys Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	03/06	AQ
Mineralys Therapeutics : Corporate Overview May 2024	13/05	PU
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05	AQ
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference	06/05	AQ
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024	02/05	AQ
Mineralys Therapeutics : Corporate Overview March 2024	21/03	PU
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	21/03	AQ
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024	13/03	AQ
Mineralys Therapeutics Announces $120 Million Private Placement Financing	08/02	AQ
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference	29/01	AQ
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer	04/01	AQ
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension	21/12	AQ
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023	11/11	AQ
Mineralys Therapeutics to Participate in Three Upcoming Conferences	09/11	AQ
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	07/11	AQ
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting	02/11	AQ
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023	31/10/23	AQ
Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023	13/10/23	AQ
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas	14/09/23	AQ
Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023	11/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Mineralys Therapeutics, Inc.

Actions

MLYS

US6031701013

Communiqués

Filtres